Tools and equipment manufacturer Snap-On (SNA) on Thursday reported 25% increase in third-quarter net income to $2.85 per share, despite net sales edging down 0.6% to $898.1 million. The earnings were helped by lower operating expenses during the quarter.
Excluding special items, the company earned $2.88 per share, higher than $2.85 per share expected by analysts.

Revenue for the quarter, which was impacted by headwinds from forex translations, was still higher than $928.69 million projected by analysts.
“While we experienced sales turbulence in our Repair Systems & Information Group this quarter, we believe the vehicle repair markets in which we operate remain robust and afford ongoing opportunity,” Nick Pinchuk said.
Sales in the Snap-On Tools group slipped 1% during the quarter to $389.8 million, while that at the Commercial & Industrial Group increased 5% to $330.2 million. Meanwhile, Repair Systems & Information Group reported a sale decline of 5.7%.
Textron crashes after missing Q3 estimates and narrowing guidance
The Kenosha, Wisconsin-based company expects capital expenditures for the full year to be in the range of $90 million to $100 million. Meanwhile, effective tax rate for this period is expected between 24% and 25%.
SNA shares have declined 4% so far this year. The stock closed 2.3% in red on Wednesday.
Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs